We Embody a Legacy of Incredible Discoveries, Exploring the Boundaries of Innovation and Science
At Zenovel, we integrate our extensive expertise across a wide range of domains, from Good Clinical Practice to Regulatory Affairs, to present valuable insights and thought leadership. Each blog reflects our intense dedication to innovation, offering a forum to share our perspectives, groundbreaking ideas, and industry expertise. Through our blogs, we hope to uplift, inform, and support scientific, medical, and pharmaceutical innovation.
In the global pharmaceutical market, compliance transcends mere regulatory adherence; it plays a pivotal role in facilitating international trade. A
The pharmaceutical industry is facing a convergence of innovation and regulation as it approaches 2026, with GxP services playing a
The recent update of ICH E6(R3) marks a significant evolution in clinical trial execution, transitioning from a compliance-centric approach to
In the pharmaceutical industry, particularly in India’s expanding market, the regulatory pathway is a crucial determinant that influences the transition
In the current pharmaceutical environment, the integrity of a company’s supply chain relies heavily on its weakest link, particularly concerning
In clinical research, Good Clinical Practice (GCP) sets ethical and quality standards. Non-compliance during audits poses systemic risks to patient
In the ever- changing pharmaceutical sector, studies of bioavailability (BA) and bioequivalence (BE) are essential to the approval of both name-brand and generic medications. BA/BE studies have grown in significance during the last thirty years, becoming essential for guaranteeing the safety and therapeutic effectiveness of pharmaceutical goods. Since these studies
Good Manufacturing Practices Audit: At Zenovel, we prioritizes maintaining high quality standards in the pharmaceutical supply chain through GMP audits, ensuring compliance with health authority regulations, industry best practices, and current standards. As regulatory requirements evolve, there’s a growing need for enhanced vigilance and Quality Risk Management during the audit
Overview of Regulatory Oversight in Life Sciences and Pharmaceutical Companies Regulatory agencies including the FDA, EMA, PMDA, HPRA, CDSCO, and others keep a vigilant eye on the life sciences and pharmaceutical sector. These organisations are committed to safeguarding patient safety and drug-product quality. In fiscal year 2023, the FDA
Understanding Nitrosamine Impurities in Pharmaceuticals: Nitrosamines, particularly N-nitrosamines, are probable or possible human carcinogens. They can form during the synthesis of active pharmaceutical ingredients (APIs) or during the storage of finished drug products. FDA guidance emphasizes the need for risk assessment, mitigation strategies, and regulatory compliance to control nitrosamine levels.
Introduction: In-process monitoring is a critical component of ensuring the quality and reliability of BA/BE studies, especially those involving drug-drug interactions (DDIs). For DDI studies, in-process monitoring is particularly crucial due to the complex nature of interactions, the need for precise data, and the potential impact on patient safety. Key
Abstract For the past few years, regulatory bodies, industry advocacy groups, and private companies have been tackling the concept of incorporating risk into the design of clinical trials and customizing monitoring strategies based on those risks to achieve higher-quality outcomes. Regulatory guidance like ICH and FDA encourag sponsors to adopt
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Write to us : bd@zenovel.com
Copyright © 2026 Zenovel. All rights reserved.
